Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Company delivers strongest quarter to date with worldwide Ocaliva® net sales of $65.9 million in the second quarter of 2019, representing 53% growth versus the prior year quarter
U.S. NDA filing for NASH on track for third quarter of 2019; EU MAA filing for NASH projected for fourth quarter of 2019; NASH launch preparations accelerating
Advancing industry-leading NASH clinical development program;
Completed target enrollment for the clinical outcomes cohort of the Phase 3 REGENERATE study, with more than 2,400 patients randomized
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended June 30, 2019 and provided an update on its industry-leading nonalcoholic steatohepatitis (“NASH”) clinical development program.
“We are pleased with our team’s outstanding commercial execution in the second quarter, as we continued to gain traction with community gastroenterologists and drove growth in our PBC business,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept. “We’ve also made significant progress in our NASH launch preparations and remain on track to submit our NDA to the FDA seeking accelerated approval of OCA for NASH in the U.S. later this quarter. We have established a strong commercial foundation in PBC and continue to believe that advanced fibrosis due to NASH represents a blockbuster opportunity. Recent changes in the competitive landscape and the insights we’ve collected from physicians, payers and patients have reinforced our conviction that OCA, if approved, is in a unique position to address the significant unmet medical need for an antifibrotic therapy intended to treat this serious disease.”
NASH Clinical Development Program Updates
Intercept’s lead product candidate is obeticholic acid (“OCA”) for the potential treatment of NASH. In February 2019, Intercept announced positive topline results from the 18-month interim analysis of its pivotal Phase 3 REGENERATE study in patients with liver fibrosis due to NASH. This was the first successful Phase 3 study readout in this patient population and the results are intended to serve as the basis for seeking accelerated approval in the U.S. and submitting a marketing authorization application (“MAA”) in Europe.
The REGENERATE study is planned to continue to confirm benefit on clinical outcomes on a post-marketing basis and Intercept has now completed target enrollment for the clinical outcomes cohort of REGENERATE. The end-of-study analysis will evaluate the effect of OCA on all-cause mortality and liver-related clinical outcomes, as well as long-term safety. With more than 2,400 patients randomized, the REGENERATE study is the largest and most advanced Phase 3 study in patients with liver fibrosis due to NASH.
Intercept is also currently conducting a pivotal Phase 3 study of OCA in NASH patients with compensated cirrhosis, known as the REVERSE study. Intercept is expanding the size of its REVERSE study from 540 patients to approximately 900 patients and extending the duration of the study from 12 to 18 months. The primary histologic endpoint of fibrosis improvement with no worsening of NASH achieved by OCA in the REGENERATE study will now be evaluated in REVERSE based on the same duration of treatment. The momentum seen in REVERSE enrollment has continued following the announcement of the positive topline results of REGENERATE in February 2019 and Intercept therefore continues to anticipate completion of REVERSE target enrollment by the end of 2019.
“Our decision to expand the REVERSE study and extend the duration of treatment further bolsters our confidence in the ability of the study to meet its objectives and demonstrate the safety and efficacy of OCA in NASH patients with compensated cirrhosis,” said Christian Weyer, M.D., M.A.S., Intercept's Executive Vice President, Research & Development. “As the only Phase 3 study currently being conducted in this more advanced segment of the NASH population, we’ve been pleased with the strong momentum we’ve seen in screening and randomization rates, and even after expanding REVERSE, remain on track to complete target enrollment this year.”
Ocaliva® (obeticholic acid) Commercial Highlights
We recognized $65.9 million of worldwide Ocaliva net sales in the second quarter of 2019, as compared to $43.2 million in the prior year quarter. Ocaliva net sales in the second quarter of 2019 were comprised of U.S. net sales of $50.7 million and ex-U.S. net sales of $15.2 million, as compared to U.S. net sales of $34.5 million and ex-U.S. net sales of $8.7 million in the prior year quarter.
Ocaliva was approved in the United States by the FDA in May 2016 and by the European Commission in December 2016 for the treatment of primary biliary cholangitis (“PBC”) in combination with ursodeoxycholic acid (“UDCA”) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Since December 2016, Ocaliva has also received regulatory approval in several of our target markets outside the United States and Europe, including Canada, Israel and Australia.
Selected Second Quarter 2019 Financial Results
We recognized $66.3 million in total revenue in the second quarter of 2019, as compared to $43.6 million in total revenue in the prior year quarter. Total revenue in the second quarter of 2019 included $65.9 million of Ocaliva net sales and approximately $0.4 million of licensing revenue, as compared to $43.2 million and approximately $0.4 million, respectively, in the prior year quarter.
Our cost of sales was $0.7 million in the second quarter of 2019, as compared to $0.7 million in the prior year quarter. Our cost of sales for the quarters ended June 30, 2019 and 2018 consisted primarily of packaging, labeling, materials and related expenses.
Our selling, general and administrative expenses increased to $69.7 million in the second quarter of 2019, up from $65.2 million in the prior year quarter. The increase was primarily driven by increases in NASH launch preparation activities.
Our research and development expenses increased to $59.6 million in the second quarter of 2019, up from $47.4 million in the prior year quarter. The increase was primarily driven by increases in NASH development program expenses and costs associated with the preparation of the NASH NDA submission.
In the quarters ended June 30, 2019 and 2018, we recorded $130.0 million and $113.4 million, respectively, in total operating expenses and $113.0 million and $98.1 million, respectively, in non-GAAP adjusted operating expenses, which excludes non-cash stock-based compensation expense of $14.8 million and $14.1 million, respectively, and depreciation and amortization expense of $2.2 million and $1.1 million, respectively.
References in this press release to “non-GAAP adjusted operating expenses” mean our total operating expenses, as calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), adjusted for the effects of two non-cash items: stock-based compensation and depreciation and amortization. See “Non-GAAP Financial Measures” below. A reconciliation of non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading “Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses.”
Interest expense in the quarters ended June 30, 2019 and 2018 was $9.9 million and $7.6 million, respectively. For the quarter ended June 30, 2019, interest expense related to the $460.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2023 (the “2023 Convertible Notes”) that we issued in July 2016 and the $230 million aggregate principal amount of 2.00% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) that we issued in May 2019. For the quarter ended June 30, 2018, interest expense related to the 2023 Convertible Notes.
In the second quarter of 2019, we reported a net loss of $71.4 million, down from a net loss of $75.2 million in the prior year quarter.
In May 2019, we issued and sold 2,760,000 shares of common stock in a registered public offering, 119,760 shares of common stock in a concurrent private placement of common stock and $230.0 million aggregate principal amount of the 2026 Convertible Notes. We received aggregate net proceeds from these transactions of approximately $450.6 million, after deducting underwriting discounts, commissions and estimated offering expenses.
As of June 30, 2019, we had cash, cash equivalents and investment debt securities available for sale of approximately $758.5 million. As of December 31, 2018, we had cash, cash equivalents and investment debt securities available for sale of approximately $436.2 million.
2019 Financial Guidance
Based on our second quarter results and our current outlook for the remainder of 2019, we are reiterating our previously announced 2019 Ocaliva net sales guidance range of between $235 million and $245 million. In addition, we are reiterating our 2019 non-GAAP adjusted operating expenses guidance range of between $470 million and $500 million. See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.
Conference Call on August 7, 2019 at 8:30 a.m. ET
We are hosting our second quarter 2019 financial results conference call and webcast on Wednesday, August 7, 2019 at 8:30 a.m. ET. The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) five minutes prior to the start time (no passcode is required). A replay of the call will be available on our website shortly following the completion of the call and will be available for two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
Non-GAAP Financial Measures
This press release presents non-GAAP adjusted operating expenses on a historical and projected basis. For the periods presented, non-GAAP adjusted operating expenses exclude from total operating expenses, as calculated and presented in accordance with GAAP, the effects of two non-cash items: stock-based compensation and depreciation and amortization. Non-GAAP adjusted operating expenses is a financial measure that has not been prepared in accordance with GAAP. Accordingly, investors should consider non-GAAP adjusted operating expenses in addition to, but not as a substitute for, total operating expenses that we calculate and present in accordance with GAAP. Among other things, our management uses non-GAAP adjusted operating expenses to establish budgets and operational goals and to manage our business. Other companies may define or use this measure in different ways. We believe that the presentation of non-GAAP adjusted operating expenses provides investors and management with helpful supplemental information relating to operating performance and trends. A table reconciling non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading “Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses”. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.
About Ocaliva® (obeticholic acid)
Ocaliva is indicated in the United States for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP) as a surrogate endpoint which is reasonably likely to predict clinical benefit, including an improvement in liver transplant free-survival. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We are conducting a Phase 4 clinical outcomes trial, which we refer to as our COBALT trial, of OCA in patients with PBC with the goal of confirming clinical benefit on a post-marketing basis.
In December 2016, Ocaliva received conditional marketing authorization in Europe for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, conditioned upon us providing further data post-approval to confirm benefit. For detailed safety information for Ocaliva 5 mg and 10 mg tablets including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European Summary of Product Characteristics that can be found on www.ema.europa.eu.
U.S. IMPORTANT SAFETY INFORMATION FOR OCALIVA IN PBC
WARNING: HEPATIC DECOMPENSATION AND FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR C OR DECOMPENSATED CIRRHOSIS
- In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with Primary Biliary Cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more frequently than recommended.
- The recommended starting dosage of OCALIVA is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event.
OCALIVA is contraindicated in PBC patients with complete biliary obstruction.
Warnings and Precautions
Hepatic Decompensation and Failure in Incorrectly-Dosed PBC Patients with Child-Pugh Class B or C or Decompensated Cirrhosis
In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in PBC patients with decompensated cirrhosis or Child-Pugh B or C hepatic impairment when OCALIVA was dosed more frequently than the recommended starting dosage of 5 mg once weekly. Reported cases typically occurred within 2 to 5 weeks after starting OCALIVA and were characterized by an acute increase in total bilirubin and/or ALP concentrations in association with clinical signs and symptoms of hepatic decompensation (e.g., ascites, jaundice, gastrointestinal bleeding, worsening of hepatic encephalopathy).
Routinely monitor patients for progression of PBC disease, including liver-related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required. Close monitoring is recommended for patients at an increased risk of hepatic decompensation. Severe intercurrent illnesses that may worsen renal function or cause dehydration (e.g., gastroenteritis), may exacerbate the risk of hepatic decompensation. Interrupt treatment with OCALIVA in patients with laboratory or clinical evidence of worsening liver function indicating risk of decompensation, and monitor the patient’s liver function. Consider discontinuing OCALIVA in patients who have experienced clinically significant liver-related adverse reactions. Discontinue OCALIVA in patients who develop complete biliary obstruction.
Liver-Related Adverse Reactions
Dose-related, liver-related adverse reactions including jaundice, worsening ascites and primary biliary cholangitis flare have been observed in clinical trials, as early as one month after starting treatment with OCALIVA 10 mg once daily up to 50 mg once daily (up to 5-times the highest recommended dosage). Monitor PBC patients during treatment with OCALIVA for elevations in liver biochemical tests and for the development of liver-related adverse reactions.
Severe pruritus was reported in 23% of PBC patients in the OCALIVA 10 mg arm, 19% of PBC patients in the OCALIVA titration arm, and 7% of PBC patients in the placebo arm in a 12-month double-blind randomized controlled trial of 216 PBC patients. Severe pruritus was defined as intense or widespread itching, interfering with activities of daily living, or causing severe sleep disturbance, or intolerable discomfort, and typically requiring medical interventions. Consider clinical evaluation of PBC patients with new onset or worsening severe pruritus. Management strategies include the addition of bile acid resins or antihistamines, OCALIVA dosage reduction, and/or temporary interruption of OCALIVA dosing.
Reduction in HDL-C
Patients with PBC generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Dose-dependent reductions from baseline in mean HDL-C levels were observed at 2 weeks in OCALIVA-treated PBC patients, 20% and 9% in the 10 mg and titration arms, respectively, compared to 2% in the placebo arm. Monitor PBC patients for changes in serum lipid levels during treatment. For PBC patients who do not respond to OCALIVA after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.
The most common adverse reactions from subjects taking OCALIVA for PBC were pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema.
Bile Acid Binding Resins
Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of OCALIVA. If taking a bile acid binding resin, take OCALIVA at least 4 hours before or 4 hours after taking the bile acid binding resin, or at as great an interval as possible.
The International Normalized Ratio (INR) decreased following coadministration of warfarin and OCALIVA. Monitor INR and adjust the dose of warfarin, as needed, to maintain the target INR range when coadministering OCALIVA and warfarin.
CYP1A2 Substrates with Narrow Therapeutic Index
Obeticholic acid, the active ingredient in OCALIVA, may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g. theophylline and tizanidine) is recommended when coadministered with OCALIVA.
Inhibitors of Bile Salt Efflux Pump
Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts including taurine conjugate of obeticholic acid in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin.
Please see Full Prescribing Information, including Boxed WARNING and Medication Guide for OCALIVA.
To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of nonalcoholic steatohepatitis (“NASH”), the safety and efficacy of our approved product, Ocaliva (obeticholic acid or “OCA”) for primary biliary cholangitis (“PBC”), and our product development candidates, including OCA for NASH, the timing and acceptance of our potential regulatory filings and potential approval of OCA for NASH or any other indications in addition to PBC, the timing and potential commercial success of OCA and any other product candidates we may develop and our strategy, future operations, future financial position, future revenue, projected costs, financial guidance, prospects, plans, objectives of management and expected market growth.
These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “possible,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. The following represent some, but not necessarily all, of the factors that could cause actual results to differ materially from historical results or those anticipated or predicted by our forward-looking statements: our ability to successfully commercialize Ocaliva for PBC; our ability to maintain our regulatory approval of Ocaliva for PBC in the United States, Europe, Canada, Israel, Australia and other jurisdictions in which we have or may receive marketing authorization; the initiation, timing, cost, conduct, progress and results of our research and development activities, preclinical studies and clinical trials, including any issues, delays or failures in identifying patients, enrolling patients, treating patients, retaining patients, meeting specific endpoints in the jurisdictions in which we intend to seek approval or completing and timely reporting the results of our NASH or PBC clinical trials; our ability to timely and cost-effectively file for and obtain regulatory approval of our product candidates, including OCA for NASH, in the United States, Europe and our other target markets; conditions that may be imposed by regulatory authorities on our marketing approvals for our products and product candidates, such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), and any related restrictions, limitations and/or warnings contained in the label of any of our products or product candidates; any potential side effects associated with Ocaliva for PBC, OCA for NASH or our other product candidates that could delay or prevent approval, require that an approved product be taken off the market, require the inclusion of safety warnings or precautions, or otherwise limit the sale of such product or product candidate; our ability to establish and maintain relationships with, and the performance of, third-party manufacturers, contract research organizations and other vendors upon whom we are substantially dependent for, among other things, the manufacture and supply of our products, including Ocaliva for PBC and, if approved, OCA for NASH, and our clinical trial activities; our ability to identify, develop and successfully commercialize our products and product candidates, including our ability to timely and successfully launch OCA for NASH, if approved; our ability to obtain and maintain intellectual property protection for our products and product candidates, including our ability to cost-effectively file, prosecute, defend and enforce any patent claims or other intellectual property rights; the size and growth of the markets for our products and product candidates and our ability to serve those markets; the degree of market acceptance of Ocaliva for PBC and, if approved, OCA for NASH or our other product candidates among physicians, patients and healthcare payors; the availability of adequate coverage and reimbursement from governmental and private healthcare payors for our products, including Ocaliva for PBC and, if approved, OCA for NASH, and our ability to obtain adequate pricing for such products; our ability to establish and maintain effective sales, marketing and distribution capabilities, either directly or through collaborations with third parties; competition from existing drugs or new drugs that become available; our ability to prevent system failures, data breaches or violations of data protection laws; costs and outcomes relating to any disputes, governmental inquiries or investigations, legal proceedings or litigation, including any securities, intellectual property, employment, product liability or other litigation; our collaborators’ election to pursue research, development and commercialization activities; our ability to establish and maintain relationships with collaborators with development, regulatory and commercialization expertise; our need for and ability to generate or obtain additional financing; our estimates regarding future expenses, revenues and capital requirements and the accuracy thereof; our use of cash and short-term investments; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to attract and retain key personnel to manage our business effectively; our ability to manage the growth of our operations, infrastructure, personnel, systems and controls; our ability to obtain and maintain adequate insurance coverage; the impact of general U.S. and foreign economic, industry, market, regulatory or political conditions, including the potential impact of Brexit; and the other risks and uncertainties identified in our periodic filings filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2018.
For more information about Intercept, please contact:
Intercept Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| ||Three Months Ended |
| ||Six Months Ended |
| || ||2019|| || || ||2018|| || || ||2019|| || || ||2018|| |
|Revenue:|| || || || || || || || || || || || || || || |
|Product revenue, net||$||65,894|| || ||$||43,169|| || ||$||117,741|| || ||$||78,327|| |
|Licensing revenue|| ||406|| || || ||406|| || || ||811|| || || ||1,211|| |
|Total revenue|| ||66,300|| || || ||43,575|| || || ||118,552|| || || ||79,538|| |
| || || || || || || || || || || || || || || || |
|Operating expenses:|| || || || || || || || || || || || || || || |
|Cost of sales|| ||677|| || || ||713|| || || ||1,251|| || || ||993|| |
|Selling, general and administrative|| ||69,683|| || || ||65,224|| || || ||146,910|| || || ||127,691|| |
|Research and development|| ||59,599|| || || ||47,415|| || || ||117,995|| || || ||96,087|| |
|Total operating expenses|| ||129,959|| || || ||113,352|| || || ||266,156|| || || ||224,771|| |
|Operating loss|| ||(63,659||)|| || ||(69,777||)|| || ||(147,604||)|| || ||(145,233||)|
| || || || || || || || || || || || || || || || |
|Other income (expense):|| || || || || || || || || || || || || || || |
|Interest expense|| ||(9,884||)|| || ||(7,589||)|| || ||(17,723||)|| || ||(15,098||)|
|Other income, net|| ||2,123|| || || ||2,173|| || || ||3,637|| || || ||3,548|| |
| || ||(7,761||)|| || ||(5,416||)|| || ||(14,086||)|| || ||(11,550||)|
|Net loss||$||(71,420||)|| ||$||(75,193||)|| ||$||(161,690||)|| ||$||(156,783||)|
| || || || || || || || || || || || || || || || |
|Net loss per common and potential common share:|| || || || || || || || || || || || || || || |
|Basic and diluted||$||(2.28||)|| ||$||(2.58||)|| ||$||(5.29||)|| ||$||(5.75||)|
| || || || || |
|Weighted average common and potential common shares outstanding:|| || || || |
|Basic and diluted|| ||31,316|| || || ||29,199|| || || ||30,542|| || || ||27,265|| |
| || || || || || || || || || || || || || || || |
Condensed Consolidated Balance Sheet Information
| ||June 30, |
| ||December 31,|
| ||(Unaudited)|| || |
|Cash, cash equivalents and investment debt securities||$||758,517|| ||$||436,160|
|Total assets||$||852,969|| ||$||509,167|
|Deferred revenue, total||$||1,622|| ||$||2,432|
|Total liabilities (2)||$||677,766|| ||$||490,037|
|Stockholders’ equity||$||175,203|| ||$||19,130|
|(1)|| ||Derived from the audited financial statements included in Intercept’s Annual Report on Form 10-K for the year ended December 31, 2018.|
|(2)|| ||Includes $545.0 million related to the 2023 Convertible Notes and the 2026 Convertible Notes (together, the “Convertible Notes”) as of June 30, 2019. Includes $371.2 million related to the 2023 Convertible Notes as of December 31, 2018. Intercept separately accounts for the debt and equity components of the Convertible Notes. The aggregate outstanding principal amount of the Convertible Notes was $690.0 million as of June 30, 2019, and the aggregate outstanding principal amount of the 2023 Convertible Notes was $460.0 million as of December 31, 2018.|
Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses
| ||Three Months Ended |
| ||Six Months Ended |
| ||2019|| ||2018|| ||2019|| ||2018|
|Total operating expenses||$||129,959|| ||$||113,352|| ||$||266,156|| ||$||224,771|
| || || || || |
|Adjustments:|| || || || |
|Stock-based compensation|| ||14,782|| || ||14,116|| || ||29,679|| || ||26,421|
|Depreciation and amortization|| ||2,210|| || ||1,138|| || ||4,610|| || ||2,428|
|Non-GAAP adjusted operating expenses||$||112,967|| ||$||98,098|| ||$||231,867|| ||$||195,922|
Source: Intercept Pharmaceuticals, Inc.